RCS - Roquefort Theraptcs. - Investor Presentation

Roquefort TherapeuticsAnnouncement

Yesterday 13:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260326:nRSZ3083Ya&default-theme=true

RNS Number : 3083Y  Roquefort Therapeutics PLC  26 March 2026

26 March 2026

Roquefort Therapeutics plc

("Roquefort Therapeutics" or the "Company")

Investor Presentation

 

Roquefort Therapeutics (LSE:ROQ), the Main Market listed biotech company,
announces that following the General Meeting held earlier today at which
shareholders approved the acquisition of the exclusive worldwide licence of
AO-252 from Coiled Therapeutics, Inc. and the name change to Coiled
Therapeutics plc, effective 27 March 2026, the leadership team will host a
live interactive presentation on the Engage Investor platform, on Monday 30
March 2026, at 2:00pm BST.

 

Dr Sotirios Stergiopoulos, Chairman Coiled Therapeutics and Sridhar Vempati,
CEO Coiled Therapeutics (together with Stephen West, current Chairman of
Roquefort Therapeutics) will present.

 

The Company welcomes all current shareholders and interested investors to
join, and encourages investors to pre-submit questions. Investors can also
submit questions at any time during the live presentation.

 

Investors can sign up to Engage Investor at no cost and follow the Company
from their personalised investor hub, and can register interest in this event
here:

https://engageinvestor.news/ROQ_IP_0326
(https://urldefense.com/v3/__https:/engageinvestor.news/ROQ_IP_0326__;!!IfJP2Nwhk5Z0yJ43lA!IDbi3lnshvqoJLxfvGONZ2Q9-GHaobeymvOBEjanUCAN3iMUQ0mpwqs53hF2o3Le7HjsaT7gMtwLVopGi6-wuciLfexAa9WBwQc$)

 

 

-ENDS-

 
Enquiries:
 Roquefort Therapeutics plc                                    +44 (0)20 3918 8633

 Stephen West (Chairman)

 SP Angel Corporate Finance LLP (Joint Broker)                 +44 (0)20 3470 0470

 David Hignell / Adam Cowl / Devik Mehta (Corporate Finance)

 Vadim Alexandre / Rob Rees (Corporate Broking)

 Shard Capital Partners LLP (Joint Broker)                     +44 (0)20 4530 6926

 Damon Heath

 CPS Capital Group Pty Ltd (Joint Broker)                      +61 (0)8 9223 2222

 Jason Peterson / David Valentino

 Burson Buchanan (Public Relations)                            +44 (0)20 7466 5000

 Henry Harrison Topham / Jamie Hooper / Toto Berger

 

LEI: ‎254900P4SISIWOR9RH34

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAUNAURNRUOUAR



            Copyright 2019 Regulatory News Service, all rights reserved